NORAD regulates epithelial‑mesenchymal transition of non‑small cell lung cancer cells via miR‑422a Corrigendum in /10.3892/mmr.2021.12178

Chen,Zhikun; Che,Qin; Xie,Chunxue

doi:10.3892/mmr.2020.11750

NORAD regulates epithelial‑mesenchymal transition of non‑small cell lung cancer cells via miR‑422a

Corrigendum in: /10.3892/mmr.2021.12178

Authors:
- Zhikun Chen
- Qin Che
- Chunxue Xie
View Affiliations

Affiliations: Department of Emergency, Jingmen No. 1 People's Hospital, Jingmen, Hubei 448000, P.R. China, Department of Infectious Diseases, Jingmen No. 1 People's Hospital, Jingmen, Hubei 448000, P.R. China, Department of General Practice, Jingmen No. 1 People's Hospital, Jingmen, Hubei 448000, P.R. China
Published online on: December 3, 2020 https://doi.org/10.3892/mmr.2020.11750
Article Number: 111
Copyright: © Chen et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The poor prognosis of non‑small cell lung cancer (NSCLC) is related to epithelial‑mesenchymal transition (EMT). Recent studies demonstrated that non‑coding RNA activated by DNA damage (NORAD) displays a carcinogenic effect and targets microRNA (miR)‑422a, which may be involved in tumor cell migration and invasion. The aim of the present study was to investigate the effect of NORAD on NSCLC cell EMT and the underlying mechanism. Reverse transcription‑quantitative PCR and western blotting were performed to detect the expression levels of long non‑coding RNAs, miRNAs and mRNAs. Cell viability, migration and invasion were detected by conducting Cell Counting Kit‑8, wound healing and Transwell assays, respectively. The target of NORAD was predicted using starBase and further confirmed by conducting a dual‑luciferase reporter assay. The results indicated that NORAD expression was significantly increased in lung cancer tissues and cells compared with adjacent healthy tissues and cells. Compared with the control groups, NORAD overexpression promoted SK‑MES‑1 cell viability, migration and invasion, whereas NORAD knockdown resulted in the opposite effects in A549 cells. Moreover, miR‑422a, which was predicted to be a target of NORAD, displayed lower expression levels in lung cancer tissues compared with adjacent healthy tissues. In addition, miR‑422a overexpression partially reversed NORAD overexpression‑induced increases in SK‑MES‑1 cell viability, migration, invasion and EMT. In addition, miR‑422a knockdown partially reversed the effects of NORAD knockdown. The present study suggested that NORAD regulated lung cancer cell EMT by regulating the expression of miR‑422a, providing a potential therapeutic target for the intervention of the development of NSCLC.

View Figures

View References

1	Xu-Welliver M and Carbone DP: Blood-based biomarkers in lung cancer: Prognosis and treatment decisions. Transl Lung Cancer Res. 6:708–712. 2017. View Article : Google Scholar : PubMed/NCBI
2	Cha G, Xu J, Xu X, Li B, Lu S, Nanding A, Hu S and Liu S: High expression of CIP2A protein is associated with tumor aggressiveness in stage I–III NSCLC and correlates with poor prognosis. Onco Targets Ther. 10:5907–5914. 2017. View Article : Google Scholar : PubMed/NCBI
3	Miller KD, Siegel RL, Lin CC, Mariotto AB, Kramer JL, Rowland JH, Stein KD, Alteri R and Jemal A: Cancer treatment and survivorship statistics, 2016. CA Cancer J Clin. 66:271–289. 2016. View Article : Google Scholar : PubMed/NCBI
4	Arbour KC and Riely GJ: Systemic therapy for locally advanced and metastatic non-small cell lung cancer: A review. JAMA. 322:764–774. 2019. View Article : Google Scholar : PubMed/NCBI
5	Yang Z, Wang H, Xia L, Oyang L, Zhou Y, Zhang B, Chen X, Luo X, Liao Q and Liang J: Overexpression of PAK1 correlates with aberrant expression of EMT markers and poor prognosis in non-small cell lung cancer. J Cancer. 8:1484–1491. 2017. View Article : Google Scholar : PubMed/NCBI
6	Rokavec M, Kaller M, Horst D and Hermeking H: Pan-cancer EMT-signature identifies RBM47 down-regulation during colorectal cancer progression. Sci Rep. 7:46872017. View Article : Google Scholar : PubMed/NCBI
7	Krebs AM, Mitschke J, Lasierra Losada M, Schmalhofer O, Boerries M, Busch H, Boettcher M, Mougiakakos D, Reichardt W, Bronsert P, et al: The EMT-activator Zeb1 is a key factor for cell plasticity and promotes metastasis in pancreatic cancer. Nat Cell Biol. 19:518–529. 2017. View Article : Google Scholar : PubMed/NCBI
8	Tong D, Liu Q, Liu G, Xu J, Lan W, Jiang Y, Xiao H, Zhang D and Jiang J: Metformin inhibits castration-induced EMT in prostate cancer by repressing COX2/PGE2/STAT3 axis. Cancer Lett. 389:23–32. 2017. View Article : Google Scholar : PubMed/NCBI
9	Ye X, Brabletz T, Kang Y, Longmore GD, Nieto MA, Stanger BZ, Yang J and Weinberg RA: Upholding a role for EMT in breast cancer metastasis. Nature. 547:E1–E3. 2017. View Article : Google Scholar : PubMed/NCBI
10	Baek SH, Ko JH, Lee JH, Kim C, Lee H, Nam D, Lee J, Lee SG, Yang WM, Um JY, et al: Ginkgolic acid inhibits invasion and migration and TGF-β-induced EMT of lung cancer cells through PI3K/Akt/mTOR inactivation. J Cell Physiol. 232:346–354. 2017. View Article : Google Scholar : PubMed/NCBI
11	Otsuki Y, Saya H and Arima Y: Prospects for new lung cancer treatments that target EMT signaling. Dev Dyn. 247:462–472. 2018. View Article : Google Scholar : PubMed/NCBI
12	Ricciuti B, Mencaroni C, Paglialunga L, Paciullo F, Crinò L, Chiari R and Metro G: Long noncoding RNAs: New insights into non-small cell lung cancer biology, diagnosis and therapy. Med Oncol. 33:182016. View Article : Google Scholar : PubMed/NCBI
13	Gong WJ, Peng JB, Yin JY, Li XP, Zheng W, Xiao L, Tan LM, Xiao D, Chen YX, Li X, et al: Association between well-characterized lung cancer lncRNA polymorphisms and platinum-based chemotherapy toxicity in Chinese patients with lung cancer. Acta Pharmacol Sin. 38:581–590. 2017. View Article : Google Scholar : PubMed/NCBI
14	Tan BS, Yang MC, Singh S, Chou YC, Chen HY, Wang MY, Wang YC and Chen RH: LncRNA NORAD is repressed by the YAP pathway and suppresses lung and breast cancer metastasis by sequestering S100P. Oncogene. 38:5612–5626. 2019. View Article : Google Scholar : PubMed/NCBI
15	Chen T, Qin S, Gu Y, Pan H and Bian D: Long non-coding RNA NORAD promotes the occurrence and development of non-small cell lung cancer by adsorbing MiR-656-3p. Mol Genet Genomic Med. 7:e7572019. View Article : Google Scholar : PubMed/NCBI
16	Gao W, Weng T, Wang L, Shi B, Meng W, Wang X, Wu Y, Jin L and Fei L: Long noncoding RNA NORAD promotes cell proliferation and glycolysis in nonsmall cell lung cancer by acting as a sponge for miR1365p. Mol Med Rep. 19:5397–5405. 2019.PubMed/NCBI
17	Zou Y, Chen Y, Yao S, Deng G, Liu D, Yuan X, Liu S, Rao J, Xiong H, Yuan X, et al: MiR-422a weakened breast cancer stem cells properties by targeting PLP2. Cancer Biol Ther. 19:436–444. 2018. View Article : Google Scholar : PubMed/NCBI
18	Jin X and Xie C: MA02. 07 Evaluation of exosomal miRNAs from plasma as potential biomarker for NSCLC. J Thoracic Oncol. 12 (Suppl):S350–S351. 2017. View Article : Google Scholar
19	Li H, Wang X, Wen C, Huo Z, Wang W, Zhan Q, Cheng D, Chen H, Deng X, Peng C and Shen B: Long noncoding RNA NORAD, a novel competing endogenous RNA, enhances the hypoxia-induced epithelial-mesenchymal transition to promote metastasis in pancreatic cancer. Mol Cancer. 16:1692017. View Article : Google Scholar : PubMed/NCBI
20	Yang X, Cai JB, Peng R, Wei CY, Lu JC, Gao C, Shen ZZ, Zhang PF, Huang XY, Ke AW, et al: The long noncoding RNA NORAD enhances the TGF-β pathway to promote hepatocellular carcinoma progression by targeting miR-202-5p. J Cell Physiol. 234:12051–12060. 2019. View Article : Google Scholar : PubMed/NCBI
21	Zuo ZK, Gong Y, Chen XH, Ye F, Yin ZM, Gong QN and Huang JS: TGFβ1-induced LncRNA UCA1 upregulation promotes gastric cancer invasion and migration. DNA Cell Biol. 36:159–167. 2017. View Article : Google Scholar : PubMed/NCBI
22	Feng SQ, Zhang XY, Fan HT, Sun QJ and Zhang M: Up-regulation of LncRNA MEG3 inhibits cell migration and invasion and enhances cisplatin chemosensitivity in bladder cancer cells. Neoplasma. 65:925–932. 2018. View Article : Google Scholar : PubMed/NCBI
23	Xu M, Chen X, Lin K, Zeng K, Liu X, Pan B, Xu X, Xu T, Hu X, Sun L, et al: The long noncoding RNA SNHG1 regulates colorectal cancer cell growth through interactions with EZH2 and miR-154-5p. Mol Cancer. 17:1412018. View Article : Google Scholar : PubMed/NCBI
24	Li L, Wang Y, Zhang X, Huang Q, Diao Y, Yin H and Liu H: Long non-coding RNA HOXD-AS1 in cancer. Clin Chim Acta. 487:197–201. 2018. View Article : Google Scholar : PubMed/NCBI
25	Zhou K, Ou Q, Wang G, Zhang W, Hao Y and Li W: High long non-coding RNA NORAD expression predicts poor prognosis and promotes breast cancer progression by regulating TGF-β pathway. Cancer Cell Int. 19:632019. View Article : Google Scholar : PubMed/NCBI
26	Tong L, Ao Y, Zhang H, Wang K, Wang Y and Ma Q: Long noncoding RNA NORAD is upregulated in epithelial ovarian cancer and its downregulation suppressed cancer cell functions by competing with miR-155-5p. Cancer Med. 8:4782–4791. 2019. View Article : Google Scholar : PubMed/NCBI
27	Wang X, Zou J, Chen H, Zhang P, Lu Z, You Z and Sun J: Long noncoding RNA NORAD regulates cancer cell proliferation and migration in human osteosarcoma by endogenously competing with miR-199a-3p. IUBMB Life. 71:1482–1491. 2019. View Article : Google Scholar : PubMed/NCBI
28	Tao W, Li Y, Zhu M, Li C and Li P: LncRNA NORAD promotes proliferation and inhibits apoptosis of gastric cancer by regulating miR-214/Akt/mTOR axis. Onco Targets Ther. 12:8841–8851. 2019. View Article : Google Scholar : PubMed/NCBI
29	Zhang H and Guo H: Long non-coding RNA NORAD induces cell proliferation and migration in prostate cancer. J Int Med Res. 47:3898–3904. 2019. View Article : Google Scholar : PubMed/NCBI
30	Yang X, Yan Y, Chen Y, Li J and Yang J: Involvement of NORAD/miR-608/STAT3 axis in carcinostasis effects of physcion 8-O-β-glucopyranoside on ovarian cancer cells. Artif Cells Nanomed Biotechnol. 47:2855–2865. 2019. View Article : Google Scholar : PubMed/NCBI
31	Liu J, Li H, Zheng B, Sun L, Yuan Y and Xing C: Competitive endogenous RNA (ceRNA) regulation network of lncRNA-miRNA-mRNA in colorectal carcinogenesis. Dig Dis Sci. 64:1868–1877. 2019. View Article : Google Scholar : PubMed/NCBI
32	He Z, Li Z, Zhang X, Yin K, Wang W, Xu Z, Li B, Zhang L, Xu J, Sun G, et al: MiR-422a regulates cellular metabolism and malignancy by targeting pyruvate dehydrogenase kinase 2 in gastric cancer. Cell Death Dis. 9:5052018. View Article : Google Scholar : PubMed/NCBI
33	Yan DG, Liu N, Chao M, Tu YY and Liu WS: SP1-induced upregulation of long noncoding RNA LINC00313 contributes to papillary thyroid cancer progression via the miR-422a. Eur Rev Med Pharmacol Sci. 23:1134–1144. 2019.PubMed/NCBI
34	Li WQ, Zhang JP, Wang YY, Li XZ and Sun L: MicroRNA-422a functions as a tumor suppressor in non-small cell lung cancer through SULF2-mediated TGF-β/SMAD signaling pathway. Cell Cycle. 18:1727–1744. 2019. View Article : Google Scholar : PubMed/NCBI
35	Zhu SP, Wang JY, Wang XG and Zhao JP: Long intergenic non-protein coding RNA 00858 functions as a competing endogenous RNA for miR-422a to facilitate the cell growth in non-small cell lung cancer. Aging. 9:475–486. 2017. View Article : Google Scholar : PubMed/NCBI
36	Pastushenko I, Brisebarre A, Sifrim A, Fioramonti M, Revenco T, Boumahdi S, Van Keymeulen A, Brown D, Moers V, Lemaire S, et al: Identification of the tumour transition states occurring during EMT. Nature. 556:463–468. 2018. View Article : Google Scholar : PubMed/NCBI
37	Mahmood MQ, Ward C, Muller HK, Sohal SS and Walters EH: Epithelial mesenchymal transition (EMT) and non-small cell lung cancer (NSCLC): A mutual association with airway disease. Med Oncol. 34:452017. View Article : Google Scholar : PubMed/NCBI
38	Yang F, Yu N, Wang H, Zhang C, Zhang Z, Li Y, Li D, Yan L, Liu H and Xu Z: Downregulated expression of hepatoma-derived growth factor inhibits migration and invasion of prostate cancer cells by suppressing epithelial-mesenchymal transition and MMP2, MMP9. PLoS One. 13:e01907252018. View Article : Google Scholar : PubMed/NCBI
39	Paolillo M and Schinelli S: Extracellular matrix alterations in metastatic processes. Int J Mol Sci. 20:49472019. View Article : Google Scholar
40	Noh MG, Oh SJ, Ahn EJ, Kim YJ, Jung TY, Jung S, Kim KK, Lee JH, Lee KH and Moon KS: Prognostic significance of E-cadherin and N-cadherin expression in Gliomas. BMC Cancer. 17:5832017. View Article : Google Scholar : PubMed/NCBI
41	Liao S, Yu C, Liu H, Zhang C, Li Y and Zhong X: Long non-coding RNA H19 promotes the proliferation and invasion of lung cancer cells and regulates the expression of E-cadherin, N-cadherin, and vimentin. Onco Targets Ther. 12:4099–4107. 2019. View Article : Google Scholar : PubMed/NCBI
42	Yu SY, Peng H, Zhu Q, Wu YX, Wu F, Han CR, Yan B, Li Q and Xiang HG: Silencing the long noncoding RNA NORAD inhibits gastric cancer cell proliferation and invasion by the RhoA/ROCK1 pathway. Eur Rev Med Pharmacol Sci. 23:3760–3770. 2019.PubMed/NCBI
43	Wu L, Hu B, Zhao B, Liu Y, Yang Y, Zhang L and Chen J: Circulating microRNA-422a is associated with lymphatic metastasis in lung cancer. Oncotarget. 8:42173–42188. 2017. View Article : Google Scholar : PubMed/NCBI